|
Cataplexy
|
0.200 |
Biomarker
|
disease |
BEFREE |
Correlation between HLA-DQB1*06:02 and narcolepsy with and without cataplexy: approving a safe and sensitive genetic test in four major ethnic groups. A systematic meta-analysis.
|
30321823 |
2018 |
|
Cataplexy
|
0.200 |
Biomarker
|
disease |
BEFREE |
The results showed that HLA DQB1*0602 was present in 4 (8%) individual of controls and 20 (45.5%) patients with higher prevalence in patients with cataplexy (78.9%) than patients without cataplexy (p<0.001).
|
29149785 |
2017 |
|
Cataplexy
|
0.200 |
Biomarker
|
disease |
BEFREE |
Narcolepsy, a sleep disorder characterized by excessive daytime sleepiness, cataplexy and rapid eye movement sleep abnormalities, is tightly associated with human leukocyte antigen HLA-DQB1*06:02.
|
25256355 |
2015 |
|
Cataplexy
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Narcolepsy in African Americans is characterized by earlier symptom onset, higher Epworth Sleepiness Scale score, higher HLA-DQB1*06:02 positivity, and low cerebrospinal fluid hypocretin-1 level in the absence of cataplexy.
|
26158891 |
2015 |
|
Cataplexy
|
0.200 |
Biomarker
|
disease |
BEFREE |
The findings suggest that the presence of HLA-DQB1*06:02 may be a predictor of cataplexy in narcoleptic patients and could therefore be used as an additional diagnostic marker alongside hypocretin.
|
24571861 |
2014 |
|
Cataplexy
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
This diagnosis was defined as narcolepsy associated with cataplexy plus HLA-DQB1*06:02 positivity (no cerebrospinal fluid hypocretin-1 results available) or narcolepsy with documented low (≤ 110 pg/mL) cerebrospinal fluid hypocretin-1 level.
|
23649748 |
2013 |
|
Cataplexy
|
0.200 |
Biomarker
|
disease |
BEFREE |
Patients were included either when hypocretin deficiency was documented (CSF hypocretin-1≤110 pg/ml, n=91) or on the basis of the presence of clear cataplexy and HLA-DQB1∗0602 positivity (n=419).
|
22177342 |
2012 |
|
Cataplexy
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The prevalence of the HLA-DQB1*0602 allele was increased in idiopathic hypersomnia and in narcoleptic patients with and without cataplexy when compared to healthy subjects (p = 0.04; p = 0.03 and p < 0.0001, respectively).
|
19506770 |
2009 |
|
Cataplexy
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Narcolepsy (hypocretin deficiency), a sleep disorder characterized by sleepiness, cataplexy and rapid eye movement (REM) sleep abnormalities, is tightly associated with HLA-DRB1*1501 (M17378) and HLA-DQB1*0602 (M20432).
|
18820697 |
2008 |
|
Cataplexy
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The HLA-DQB1*0602 allele was identified in 10 (62.5%) of our 16 cataplexic subjects and in 2 (33.3%) of the 6 patients without cataplexy (p=0.24).
|
17665008 |
2007 |
|
Cataplexy
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
This study was designed to investigate the frequency of the HLA-DQB1 allele and cerebrospinal fluid (CSF) hypocretin levels in Korean narcoleptics with cataplexy as compared with those who do not have cataplexy.
|
17297265 |
2007 |
|
Cataplexy
|
0.200 |
Biomarker
|
disease |
BEFREE |
We tested sera from strictly diagnosed HLA DQB1*0602-positive narcoleptic patients with cataplexy for evidence of autoantibodies against human preprohypocretin, hypocretin 1 and 2, N-terminal leader and C-terminal peptides of preprohypocretin using enzyme-linked immunosorbent assays (ELISA).
|
16171287 |
2005 |
|
Cataplexy
|
0.200 |
Biomarker
|
disease |
BEFREE |
The objectives of the present study were to determine whether the month-of-birth pattern would (a) vary with the presence and severity of cataplexy and (b) differ for patients positive and negative for HLA-DQB1*0602.
|
15683136 |
2004 |
|
Cataplexy
|
0.200 |
Biomarker
|
disease |
BEFREE |
Association with HLA DQB1*0602 was observed in 99.4% of narcoleptics with cataplexy and in 89.5% of those without cataplexy.
|
11833861 |
2002 |
|
Cataplexy
|
0.200 |
Biomarker
|
disease |
BEFREE |
No antibody test yielded significantly positive results for the group as a whole or for subgroups of patients with cataplexy or positive HLA DQB1*0602 status.
|
12405606 |
2002 |
|
Cataplexy
|
0.200 |
Biomarker
|
disease |
BEFREE |
Subjects with definite cataplexy as observed by an experienced clinician were more frequently HLA DQB1*0602-positive than those with doubtful cataplexy, and the manifestations of cataplexy were clinically more typical in DQB1*0602-positive patients.
|
9456467 |
1997 |
|
Cataplexy
|
0.200 |
Biomarker
|
disease |
HPO |
|
|
|